Now Pharma Inc., a leading Indian pharmaceutical company, acknowledges the recent statements by U.S. President Donald Trump regarding the introduction of new tariffs on pharmaceuticals. The proposed tariffs aim to impose unprecedented levels of duties on pharmaceutical imports, creating uncertainty within the global pharmaceutical industry. ​

Impact on the Indian Pharmaceutical Sector

The United States represents a significant market for Indian pharmaceutical exports, with India supplying approximately 40% of generic formulations consumed in the U.S. The potential imposition of tariffs could disrupt this trade, affecting both the availability of affordable medications for American consumers and the operational dynamics of Indian pharmaceutical companies. ​

Strategic Measures and Market Diversification

In light of the potential tariffs, Now Pharma Inc. is proactively exploring alternative markets to mitigate possible business impacts. The company is focusing on expanding its presence in regions such as Europe, Latin America, Africa, and other emerging markets to offset potential challenges in the U.S. market. This strategic diversification aims to ensure the continued growth and stability of the company’s operations. ​

Industry Collaboration and Advocacy

Now Pharma Inc. is collaborating with industry associations and stakeholders to engage in dialogue with U.S. trade representatives and policymakers. The objective is to advocate for the mutual benefits of maintaining a fair and open trade environment that supports the availability of affordable medications and fosters innovation within the pharmaceutical sector.​

Commitment to Global Health

Despite the prevailing uncertainties, Now Pharma Inc. remains steadfast in its commitment to delivering high-quality, affordable medications to patients worldwide. The company will continue to monitor developments closely and adapt its strategies to navigate the evolving global trade landscape effectively.